Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone Results of a Prospective, Open-label Phase II Study GANESH RAGHU, W. CRAIG JOHNSON, DIANE LOCKHART, and YOLANDA MAGETO University of Washington, and Statistics and Epidemiology Research Corporation, Seattle, Washington Idiopathic pulmonary fibrosis (IPF) is a progressive clinical syndrome of unknown etiology and fatal outcome. Currently available therapies are ineffective and associated with significant adverse effects. Pirfenidone, a new, investigational antifibrotic agent, was evaluated for its tolerability and usefulness in terminally ill patients with advanced IPF. Consecutive patients with IPF and deterioration despite conventional therapy or who were unable to tolerate or unwilling to try conventional therapy were treated with oral pirfenidone. Treatment was administered on a compassionate basis (open-label). Fifty-four patients were followed for mortality, change in lung function, and adverse effects. Their mean age was 62, mean duration of symptoms 4.6 yr, and time since lung biopsy was 3.2 yr. Conventional therapy was discontinued in 38 of 46 patients; the other eight were able to decrease their prednisone dosage and eight had no previous conventional treatment. One- and 2-yr survival was 78% (95% CI 66%, 89%) and 63% (95% CI 50%, 76%), respectively. Patients whose lung functions had deteriorated prior to enrollment appeared to stabilize after beginning treatment. Adverse effects were relatively minor. The results of this study are encouraging. Pirfenidone is a promising new treatment for IPF that is well tolerated. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. AM J RESPIR CRIT CARE MED 1999;159:1061 1069. Idiopathic pulmonary fibrosis (IPF), a progressive clinical syndrome generally occurring in adults over 50 yr of age, poses significant challenges in clinical management (1 3). The syndrome is characterized by gradual onset of dyspnea, diffuse bilateral lung infiltrates as visualized on chest roentgenography, and restrictive lung disease with an increased alveolar arterial (resting or exercise) oxygen difference P(A a)o 2, and a reduced carbon monoxide diffusion capacity (DL CO ). It is characterized histologically by features of usual interstitial pneumonia (UIP) that include varying degrees of alveolitis, disruption of the pulmonary vascular bed, and fibrosis of the pulmonary parenchyma (4). Mortality rates from the disease are high; median survival from diagnosis is approximately 4 yr (5, 6). There is no known curative therapy. Previously believed to be a relatively rare disorder with a prevalence of approximately three to five cases in 100,000 individuals (7, 8), IPF is now more commonly recognized, especially in older patients (9). Although the natural history of untreated patients has not been definitively described, the clinical course generally progresses to death secondary to respiratory failure. For an individual patient, however, the course (Received in original form May 18, 1998 and in revised form October 20, 1998) Correspondence and requests for reprints should be addressed to Ganesh Raghu, M.D., F.C.C.P., F.A.C.P., Chief, Chest Clinic, University of Washington Medical Center, Box 356522, Division of Pulmonary and Critical Care Medicine, Seattle, WA 98195-6522. Am J Respir Crit Care Med Vol 159. pp 1061 1069, 1999 Internet address: www.atsjournals.org is variable and unpredictable (10). Patients are often symptomatic years prior to diagnosis, with definitive medical diagnosis and treatment beginning long after initiation of the inflammatory process in the lung. Various factors, such as younger age, early disease stage, female gender, better preserved lung function, cellular lung biopsy, or lymphocytosis in bronchoalveolar lavage at diagnosis, have been associated with a better prognosis and a favorable response to therapy with corticosteroids with or without immunosuppressive agents (6, 11). Currently available medical therapy is clearly ineffective (12) and associated with significant adverse events and morbidity (13). The U.S. Food and Drug Administration (FDA) has permitted testing of a new antifibrotic agent in this population. Pirfenidone (Deskar; MARNAC, Inc., Dallas, TX) is a pyridone molecule [5-methyl-1-phenyl-2-(1H)-pyridone]. In hamsters, pirfenidone has been shown to ameliorate bleomycin-induced pulmonary fibrosis (14). In vitro, this compound inhibits transforming growth factor beta (TGF- )-stimulated collagen synthesis, decreases the extracellular matrix, and blocks the mitogenic effect of profibrotic cytokines in adult human lung fibroblasts derived from patients with IPF (15). Because IPF is characterized by lung fibroblast proliferation, increased connective tissue synthesis, and desposition in the lung associated with TGF- and platelet-derived growth factor (PDGF), a clinical role for an antifibrotic agent such as pirfenidone is evident. This report describes the results of initial Phase II testing of pirfenidone in patients with advanced IPF. The aim of the study was to evaluate the clinical usefulness and tolerability of pirfenidone in this population.
1062 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 159 1999 METHODS Study Population This open-label, compassionate use study enrolled consecutive adult symptomatic consenting patients referred to the University of Washington Medical Center (UWMC) between March 1995 and May 1996, with a definite diagnosis of IPF. Diagnosis of IPF was based on typical clinical and histological features of UIP confirmed by surgical lung biopsy (SLB) (4, 16). Typical clinical features included radiographic progressive pulmonary infiltrates predominantly in the basilar and peripheral zones; high-resolution computed tomography (HRCT) of the chest, features of lower lobe pulmonary fibrosis with or without traction bronchiectasis, lower lobe honeycombing without ground glass opacities, and restrictive lung defect with decreased DL CO. Patients over age 65 with long-standing typical clinical features of progressive IPF in whom transbronchial lung biopsy (TLB) had not revealed granuloma, vasculitis, infection, or malignancy were also included (16). Patients had to have demonstrated progressive deterioration of IPF (as in endpoints described subsequently) despite therapy with prednisone with or without immunosuppressives (conventional therapy) and inability to tolerate or unwillingness to try conventional therapy. There had to be no other clinical explanation for patient deterioration. Patients were excluded if they had clinical or serological evidence for collagen vascular disease, a history of exposure to known fibrogenic agents, active infection, malignancy, hemoptysis, acute or subacute hypersensitivity pneumonitis, adult respiratory distress syndrome, requirement for mechanical ventilation, congestive heart failure, or renal or hepatic dysfunction. Endpoints Primary endpoints included overall survival and measurable change in lung function after 12 mo of therapy in living patients willing and able to perform repeat pulmonary function tests (PFTs). FVC, TLC, DL CO, and oxygen saturation (resting and while walking when the patient was able to walk) were measured at baseline and during follow-up using standard criteria (17). Improvement in pulmonary function measures was defined as a 10% or greater increase in predicted value of FVC or TLC, 20% or greater increase in DL CO, or 3% increase in oxygen saturation with the same fraction of inspired oxygen (FI O2 ), resting or exertional. A decrease of similar magnitude for each measure was considered a deterioration. Patients who did not demonstrate improvement or deterioration were considered stable. Intervention and Follow-up Consecutive eligible patients who had refused, not tolerated, or failed conventional therapy and were willing to discontinue that therapy were approached. After obtaining informed consent, medical history and physical examination data were collected. In assessing preentry measurements, only PFTs that were obtained in a standardized and acceptable manner (17) at comparable time points were selected from data gathered from available historical records. These records were obtained from community physician offices and local hospitals. PFTs included spirometry, measurement of FVC, TLC, DL CO, and oxygen saturation (resting and exertion if able to walk) at baseline. TLC was measured by body plethysmography and DL CO (single-breath) was corrected for hemoglobin and not corrected for alveolar gas volume. Over a period of 15 d, oral pirfenidone was slowly increased to 40 mg/ kg/d up to a maximum of 3,600 mg/d in divided doses. Study medication was continued as long as the patient was enrolled in the study (over 2 yr for many patients). Patients were informed about anticipated side effects including nausea, abdominal discomfort, dyspepsia, fatigue, and lethargy. Adjunct immunosuppressive therapy was stopped on day 1 and prednisone was tapered over a 6- to 8-wk period at a rate of 5 mg per 5- to 7-d period. Patients were not allowed to take other concurrent medications that are currently used in the treatment of IPF (including colchicine). Oxygen supplementation was continued as needed to maintain adequate saturation ( 90%). Patients were seen in clinic weekly for 2 wk, monthly for 3 mo, and then every 3 mo. Blood chemistries and hematology were measured at each follow-up. All new symptoms other than dyspnea were recorded as adverse effects. Pulmonary function was measured in patients able to perform tests and a chest roentgenogram was obtained at baseline and quarterly. All patients were followed for survival for the duration of the study regardless of whether they continued pirfenidone or not. The study protocol and informed consent were approved by the University of Washington Human Subjects Committee. Statistical Methods Changes in PFTs were statistically evaluated using a one-sample t test on the difference between first and last measurement (e.g., diagnosis and study entry or study entry and last follow-up). The mean and 95% confidence interval (CI) of the mean were computed and displayed for lung function measurements. A survivorship effect on pulmonary function measures was explored by comparing baseline means for subgroups of patients grouped by the time from entry until last follow-up. Survival estimates were computed using standard Kaplan- Meier estimates with the Greenwood formula for the 95% CI for the estimate (18). SPSS (SPSS, Inc., Chicago, IL) was used for statistical tests and S-Plus (MathSoft, Seattle, WA) for graphical displays. Data were independently monitored for accuracy against original medical records. RESULTS Fifty-four patients were enrolled, 42 with confirmation of IPF by SLB, eight with diagnosis by typical clinical features of IPF (granuloma, infection, neoplasm, and vasculitis were excluded by TLB), and four by typical clinical features alone whose features included typical HRCT findings of UIP. Mean age was 62 yr, mean duration of clinical symptoms prior to entry was 4.6 yr (range 8 mo to 15 yr), and mean time since diagnosis was 3.2 yr. Most patients (n 32) were receiving the combination of prednisone with immunosuppressives and most required oxygen supplementation (Table 1). PFTs varied greatly at entry; FVC averaged 58.8% of predicted but ranged between 26% and 108% of predicted. Similarly, DL CO ranged between 8% and 104% of predicted, mean 34.3 (Table 2). While these patients with known IPF for several years were considered to be terminally ill based on progressive subjective and objective deterioration and estimated life expectancy of less than 18 mo, two patients had normal DL CO measurements of greater than 80% of predicted. Although the exact reason for the apparent normal DL CO values in these two exceptional patients is unclear, it is conceivable that these may have been the result of TABLE 1 CHARACTERISTICS AT INITIATION OF PIRFENIDONE* Study Population (n 54) Range Method of diagnosis Surgical lung biopsy and clinical features 42 Transbronchial biopsy and clinical features 8 Clinical criteria (including HRCT features) 4 Male gender 30 Age (mean, yr) 62.3 28 80 Smoking history 31 Ethnic origin Caucasian 51 African-American 2 Hispanic 1 Duration of clinical illness (mean, yr) 4.6 8 mo 15 yr Time since diagnosis (mean, yr) 3.2 1 mo 10 yr Preentry treatment Prednisone alone 14 Prednisone with azathioprine 30 Prednisone with cyclophosphamide 2 Oxygen supplementation 32 Constant 29 On exertion or sleep 3 No treatment 8 * Values are numbers of patients unless otherwise noted.
Raghu, Johnson, Lockhart, et al.: New Treatment for Pulmonary Fibrosis 1063 TABLE 2 PULMONARY FUNCTION AT INITIATION OF PIRFENIDONE Mean SD Range FVC, % of pred 58.8 18.9 26 108 TLC, % of pred 58.7 16.5 33 97 DL CO-Sb, % of pred 34.3 17.2 8 104 O 2 saturation, resting, % 94.3 3.0 86 100 O 2 saturation, peak exertional, % 85.6 6.7 68 97 Definition of abbreviation: DL CO-Sb diffusion capacity for carbon monoxide (single breath), corrected to hemoglobin. occult technical errors or the known lack of correlation of PFTs obtained at rest with the morphological stages of pulmonary parenchymal changes in IPF. Forty-one of 54 patients completed the PFTs at 6 mo and 31 patients completed at 12 mo; the remainder were either dead or unable to perform tests at set intervals because of profound dyspnea. Twenty-one patients died during 25 mo of follow-up. The 1-yr survival was 78% (95% CI: 66%, 89%) and the 2-yr survival was 63% (95% CI: 50%, 76%) (Figure 1). Three patients eventually received lung transplantation after 9 mo, 11 mo, and 17 mo of follow-up and were censored from survival estimates at that time. Thirty-eight of 46 (83%) patients were able to discontinue prednisone within 2 mo after study entry. The remaining eight were able to decrease their daily dose of prednisone to 10 to 15 mg. All 32 patients who were taking immunosuppressives tolerated discontinuation of the immunosuppressive therapy at study entry. Review of available historical data revealed that full PFTs (FVC, TLC, DL CO, O 2 saturation) were not obtained in a standardized manner for all patients at diagnosis. Of the available PFTs that were performed in an acceptable and standardized manner (17), the individual measurements were at varying time points. Therefore, comparable and acceptable PFTs were not available for all patients during the preenrollment period. The preentry data shown in Figures 2 4 have variable numbers of available measures as expected given the inevitable difficulties of collecting appropriate historical data. Mean FVC and TLC, which decreased significantly between diagnosis and entry, stabilized after entry into the study (Figures 2 and 3). Insufficient data for DL CO measurements during preenrollment prevented a meaningful comparison between diagnosis and study entry time points. However, DL CO did appear to stabilize after study entry (Figure 4). The apparent increasing trend of PFT measures in Figures 2 4 is likely due to a survivorship effect. Figure 5 demonstrates that patients who have FVC data available at later follow-up visits generally had higher FVC values at study entry. TLC and DL CO measures also demonstrated similar apparent survivorship effects. Oxygen saturation during exertion as well as requirement for supplemental oxygen remained stable during the first 12 mo of follow-up (Figures 6A and 6B). In addition, three patients were able to discontinue supplemental oxygen use entirely without experiencing oxygen desaturation, one of whom became entirely asymptomatic 9 mo after initiation of pirfenidone and has remained so 28 mo later. At 6 mo, 29 patients demonstrated stabilized or improved lung function by FVC; 12 deteriorated. Seventeen had stabilized or improved TLC whereas seven deteriorated. Twenty-five patients had stabilized or improved DL CO and six deteriorated. Six patients, however, had died prior to the 6-mo follow-up and PFTs were not available on a considerable number (Table 3). At 1 yr, 22 demonstrated stabilized or improved FVC and Figure 1. Overall Kaplan-Meier survival curve with 95% CI.
1064 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 159 1999 Figure 2. Mean FVC with pointwise 95% CI for n available measures. nine deteriorated; 15 stabilized or improved TLC and eight deteriorated; 20 stabilized or improved DL CO and seven deteriorated. By that time 12 patients had died and one had undergone lung transplantation. Analysis of factors associated with survival indicated that patients with percentage of predicted DL CO levels less than 30% predicted (Figure 7) and advanced age ( 65 yr) were associated with decreased survival. Male gender was also moderately associated with decreased survival in Cox regression models that included DL CO and age covariates. Other PFTs were not found to be associated with survival time. A patient s smoking history was also not found to be a significant predic- Figure 3. Mean TLC with pointwise 95% CI for n available measures.
Raghu, Johnson, Lockhart, et al.: New Treatment for Pulmonary Fibrosis 1065 Figure 4. Mean diffusing capacity with pointwise 95% CI for n available measures. tor of survival (data not shown) when other important factors (age, DL CO at entry, and gender) were examined in this advanced disease patient population. There were no improvements noted in chest radiographs during the follow-up period. Gastrointestinal adverse symptoms were relatively common with 44% of patients reporting nausea (Table 4). Only two patients, however, experienced symptoms severe enough to warrant discontinuation of the drug. For most, use of over- Figure 5. Survivorship effect demonstrated by mean FVC stratified by amount of available follow-up information.
1066 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 159 1999 Figure 6. (A) Mean oxygen saturation (peak exertion) with pointwise 95% CI. (B) Mean additional oxygen requirement with pointwise 95% CI. the-counter antacids relieved the symptoms. Photosensitive skin rash was experienced by 24% of patients; four of them (8%) discontinued pirfenidone because of this rash. In all cases, the rash subsided upon discontinuation of the drug and no permanent sequelae were observed. Fatigue was noted by 42% of patients. This subsided with a decreased dosage and with reminder to take the medication with food and liquid. Fatigue did not result in any patients discontinuing the drug. There were no adverse events noted in hematology or blood chemistry. DISCUSSION Pirfenidone is a new investigational antifibrotic agent that, prior to this study, had never been used in a clinical setting. This Phase II, open-label study evaluated pirfenidone prospectively in 54 consecutive, terminally ill patients with advanced IPF. As a compassionate use protocol, the study enrolled terminally ill patients regardless of how ill or physically limited they were at the time of enrollment. In this limited number of deteriorating patients with IPF who had failed or not tolerated conventional therapy, treatment with pirfenidone arrested further decline in the majority and improved oxygenation in a few patients. The drug was well tolerated with minimal side effects which promptly subsided after discontinuation of the drug or decrease in dosage; there were no permanent sequelae to side effects. Pirfenidone did not result in any blood count or blood chemistry abnormalities. Further, treatment with pirfenidone allowed discontinuation or tapering of prednisone and immunosuppressive therapy without further loss of lung function. The results from this single group study are encouraging but not definitive. When compared with other reports of the natural history of IPF and survival rates for patients treated with conventional therapy (1, 5, 6, 11, 19, 20), the 22% 1-yr mortality and 37% 2-yr mortality observed among this termi- TABLE 3 CHANGE IN LUNG FUNCTION 6-mo Follow-up 1-yr Follow-up FVC TLC DL CO FVC TLC DL CO Stable 19/41 (46%) 10/24 (42%) 18/31 (58%) 15/31 (48%) 10/23 (43%) 11/27 (41%) Improved 10/41 (24%) 7/24 (29%) 7/31 (23%) 7/31 (23%) 5/23 (22%) 9/27 (33%) Deteriorated 12/41 (29%) 7/24 (29%) 6/31 (19%) 9/31 (29%) 8/23 (35%) 7/27 (26%) Total (with measures) 41/54 (76%) 24/54 (44%) 31/54 (57%) 31/54 (57%) 23/54 (43%) 27/54 (50%) Died before follow-up 6/54 (11%) 6/54 (11%) 6/54 (11%) 12/54 (22%) 12/54 (22%) 12/54 (22%) Transplant before follow-up 0 0 0 1/54 (2%) 1/54 (2%) 1/54 (2%) Data not available* 7/54 (13%) 24/54 (44%) 17/54 (31%) 10/54 (19%) 18/54 (33%) 14/54 (26%) * Patient alive but unable to perform PFT or keep appointment.
Raghu, Johnson, Lockhart, et al.: New Treatment for Pulmonary Fibrosis 1067 Figure 7. Kaplan-Meier survival curve stratified by DL CO. nally ill cohort is encouraging. It is conceivable that the patients entered into this study were among a minority of IPF patients who survive regardless of therapy. All of the patients in this cohort, however, had demonstrated progressive deterioration prior to enrollment or not tolerated conventional therapy, and 46 had tried adequate conventional therapy. The lack of appropriate controls, inconsistent historical data, and the small number of patients in this study is insufficient to accurately identify general improvement of pirfenidone on lung function. Upon initiation of pirfenidone and discontinuation of conventional therapy, however, measures of PFTs appeared to stabilize. Changes in measurements of PFTs at the end of 1 yr have been documented to predict long-term survival in this population (21, 22). Thus, the observed stabilization of lung function in this study is encouraging. Analysis of predictors of survival identified DL CO, age, and gender to be associated with survival in this population. Female gender, relatively young age, and higher static PFTs at diagnosis have been associated with enhanced survival and response to therapy (21, 22). Perhaps of particular importance is that pirfenidone may stabilize the DL CO measure, which in turn is predictive of a patient s survival. Further studies are necessary to establish any direct effect of pirfenidone on survival. Current therapies focus on suppressing the inflammatory process. Corticosteroids are most commonly prescribed, although a measurable favorable response is reported in only 23% of patients (6). This may be because most patients with IPF have had the disease for an extended period, long after the initiation of the inflammatory process. Thus, most patients in current clinical practice are in the fibroproliferative phase and not the early inflammatory stage, justifying a clinical role for antifibrotic agents. Class and Symptom TABLE 4 ADVERSE EFFECTS Number (Percent) Reporting Number (Percent) Discontinuing Pirfenidone Because of Adverse Effect Gastrointestinal Upper abdominal discomfort 7 (13%) 0 Abdominal bloating 6 (11%) 0 Heartburn 4 (7%) 0 Nausea 24 (44%) 2 (4%) Emesis 3 (5%) 1 (2%) Anorexia 7 (13%) 0 Diarrhea 5 (9%) 0 Constipation 2 (4%) 0 Other gastrointestinal symptom 4 (7%) 0 Any gastrointestinal symptom 35 (64%) 2 (4%) Dermatological Rash (photosensitivity) 13 (24%) 4 (7%) Itching 5 (9%) 0 Dry skin 2 (4%) 0 Peeling 2 (4%) 0 Hyperpigmentation 2 (4%) 0 Other dermatologic symptom 4 (7%) 0 Any dermatologic symptom 20 (37%) 4 (7%) Other body system Headache 1 (2%) 0 Weakness 1 (2%) 0 Fatigue 23 (42%) 0 Laboratory findings Blood chemistries 0 0 Hematology 0 0 Any adverse symptom 47 (87%) 6 (11%)
1068 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 159 1999 Prospective randomized clinical trials have been limited by the relatively low prevalence of the disease, its unpredictable course, and the adverse effect profile of currently available therapies. Data supporting the long-term use of corticosteroids is based primarily on retrospective, uncontrolled trials (23 25). More recently this drug has been combined with a second immunosuppressive agent such as azathioprine or cyclophosphamide in an attempt to use lower doses of prednisone while increasing the immunosuppressive effect of therapy. A randomized comparison of prednisone alone to the combination of prednisone and azathioprine (19) showed a benefit on survival for the combined therapy after 3 yr of follow-up. During the first year of therapy, however, there appeared to be no discernible difference. In another study comparing prednisolone alone to prednisolone in combination with cyclophosphamide, there was no difference in the therapeutic response between these two therapies (20). Significant side effects were associated with cyclophosphamide, resulting in discontinuation of therapy. The significant adverse effects associated with use of corticosteroids and immunosuppressive agents contribute to additional morbidity in these patients (13). Recent National Institutes of Health sponsored workshops have reviewed available treatment modalities for IPF and concluded that current therapies are ineffective. They recommended development and testing, in randomized trials, of new therapeutics for IPF (12, 26). Further, the committee recommended that treatment strategies be based on evolving knowledge of the fibrotic process in addition to the inflammatory process because most cases are detected in later stages of the disease when fibrosis has already set in. More recent research has shed light into the fibroblast proliferation and connective tissue synthesis by profibrotic cytokines implicated in the pathogenesis of pulmonary fibrosis (27). In vitro studies have shown that fibroblast cultures from inflammatory lung tissue can be stimulated with PDGF or serum so that they grow at a faster rate (28). The rationale to use antifibrotic agents is, thus, based on the well-known lung fibroblast proliferation associated with increased collagen synthesis and deposition of extracellular matrix components in the fibrotic human lung (27 30). Currently available antifibrotic agents include colchicine, D-penicillamine, and interferon. In a recent prospective study of a small number of patients with IPF, colchicine failed to demonstrate a significant difference in the rate of decline in lung function or mortality between the colchicine group and the control group that received prednisone (31). D-penicillamine interferes with collagen cross-linking in vitro. Retrospective studies of the efficacy of D-penicillamine have showed no significant benefit for this therapy and the drug is associated with significant adverse effects (25). -interferon has been demonstrated to inhibit lung fibroblast proliferation and collagen synthesis (32). It has not been used, however, in IPF. It has been suggested that IPF should be divided into UIP and other disorders such as nonspecific interstitial pneumonia (NSIP) (4, 33). Clinically, these two entities might be differentiated by patient age with UIP patients presenting in the sixth or later decade of life compared with a generally younger age group of patients diagnosed with NSIP. This younger cohort appears to respond better to steroid therapy than older patients with UIP. The effect of pirfenidone may have been blunted by the relative efficacy in younger patients presenting with NSIP. All 12 of the 54 patients (22%) who were younger than 55 yr of age, however, had SLB evidence of UIP. Whether there is a differential effect of pirfenidone in younger patients compared with older or UIP versus NSIP cannot be discerned from this study. IPF is a relentless progressive disorder. First described as a fulminating case in 1933, this clinical syndrome remains fatal without effective medical therapy either to alleviate the symptoms or to improve the outcome. Corticosteroids with or without adjunct immunosuppressive regimen, although considered conventional therapy, is nonspecific, associated with significant adverse effects and poor quality of life, and response rates are only 20 to 30%. Lung transplantation is an option only for selected patients with IPF who are generally under 60 to 65 yr of age. In addition, it is associated with significant complications and the survival rates are approximately 70% at 1 yr and 50% at 5 yr,* which warrants the need for new treatment with antifibrotic agents. Currently available antifibrotics such as colchicine appear to be well tolerated but their efficacy remains to be determined. Future therapeutic strategies should continue to be based on the pathogenesis of pulmonary fibrosis, for example, looking at the effectiveness of antioxidants, cytokine inhibitors, surfactants, or other antifibrotic agents (12). In this Phase II trial, pirfenidone has shown promise despite a survivorship effect in halting the clinical decline and in reducing mortality in patients with advanced IPF. Future IPF-related clinical studies should, however, take into consideration the inherent bias associated with survivorship effect in analyzing PFTs and other objective measurements. In addition, future clinical trials investigating the efficacy of any medical regimen for IPF must be prospective, randomized, controlled, preferably double-blinded, and enroll patients early in the disease course. Such efficacy studies must enroll extremely well-defined patient populations and will require enrollment of a sufficiently large number of patients to draw definitive conclusions. Only carefully designed and well-conducted multicenter clinical trials can accomplish this. Without the joint, collaborative and concerted efforts of clinicians, patients, government, and industry, the efficacy of new treatment regimens for IPF will not be documented. Considering the high mortality rates associated with IPF and evolving clinical knowledge regarding monitoring clinical status, appropriate efficacy endpoints for such trials should include outcome measures at least at the end of 1 yr of change in static pulmonary function, oxygenation, HRCT findings, quality of life, and survival. Pirfenidone appears to be a promising new antifibrotic drug for the treatment of IPF that deserves a well-designed randomized controlled clinical trial to adequately test the efficacy and safety of this new agent. Because patients with higher DL CO ( 30% predicted value) at entry were associated with longer survival in this study, future trials of pirfenidone and other antifibrotic agents should focus on early treatment periods before DL CO levels seriously decrease. Hopefully, ongoing clinical trials will document the efficacy of antifibrotic agents such as pirfenidone in IPF patients. Acknowledgment : We are greatly indebted to patients, their families, and Washington State Community and Academic Pulmonary Physicians, without whose voluntary enthusiastic support this study would not have been possible. We greatly appreciate the generosity of Nancy A. Cox, M.D., Ph.D., and Solomon B. Margolin, M.S., Ph.D., (MARNAC, Inc., Dallas, TX) in providing pirfenidone for this study and for providing preliminary laboratory and background data concerning the drug which prompted this study. We genuinely appreciate the UWMC Investigational Drug Service s dedication to providing reliable drug accountability, dispensation, and handling of pirfenidone. Assistance by Ms. Ruth McBride in manuscript preparation is greatly appreciated. * Accumulated data from International Lung Transplant Registry, St. Louis, MO.
Raghu, Johnson, Lockhart, et al.: New Treatment for Pulmonary Fibrosis 1069 References 1. Meier-Sydow, J., S. M. Weiss, R. Buhl, M. Rust, and G. Raghu. 1994. Idiopathic pulmonary fibrosis: current clinical concepts and challenges in management. Semin. Respir. Crit. Care Med. 15:77 96. 2. Park, D. J., and G. Raghu. Idiopathic pulmonary fibrosis. In W. N. Kelley, editor. Textbook of Internal Medicine, 3rd ed. Lippincott-Raven, New York. 1996. 3. Lynch, J. P., and G. Toews. 1997. Idiopathic pulmonary fibrosis. In Elias Fishman and Kaiser Grippi, editors. Pulmonary Diseases and Disorders, 3rd ed. McGraw-Hill. 4. Katzenstein, A. A., and J. L. Myers. 1998. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. Rev. Respir. Crit. Care Med. 157:1301 1315. 5. Izumi, T., S. Nagai, Y. Kondo, and M. Tamura. 1993. Ten-year follow-up of 222 patients with idiopathic pulmonary fibrosis a nation-wide survey report in Japan (abstract). Am. Rev. Respir. Dis. 145:A218. 6. Turner-Warwick, M., B. Burrows, and A. Johnson. 1980. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 35:171 180. 7. Crystal, R. G., P. B., Bitterman, S. I. Rennard, et al. 1984. Interstitial lung disease of unknown cause disorders characterized by chronic inflammation of the lower respiratory tract. N. Engl. J. Med. 310:154 166. 8. DuBois, R. M. 1990. Cryptogeic fibrosing alveolitis. In R. A. L. Brewis, G. J. Gibson, and D. M. Geddes, editors. Respiratory Medicine. Baillere Tindall, London. 1088 1103. 9. Coultas, D. B., R. E. Zumwalt, W. C. Black, and R. E. Sobonya. 1994. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 150:967 972. 10. Raghu, G. 1987. Idiopathic pulmonary fibrosis: a rational clinical approach. Chest 92:148 154. 11. Rudd, R. M., P. L. Haslam, and M. Turner-Warwick. 1981. Cryptogenic fibrosing alveolitis: relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am. Rev. Respir. Dis. 124:1 8. 12. Hunninghake, G. W., and A. R. Kalica. 1995. Approaches to the treatment of pulmonary fibrosis: workshop summary. Am. J. Respir. Crit. Care Med. 151:915 918. 13. Lynch, J. P., and W. J. McCune. 1997. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am. J. Respir. Crit. Care Med. 155:395 429. 14. Iyer, S. N., J. S. Wild, M. J. Schiedt, D. M. Hyde, S. B. Margolin, and S. N. Giri. 1995. Dietary intake of pirfenidone ameliorates bleomycininduced fibrosis in hamsters. J. Lab. Clin. Med. 125:779 785. 15. Lurton, J. M., T. Trejo, A. S. Narayanan, and G. Raghu. 1996. Pirfenidone inhibits the stimulatory effects of profibrotic cytokines on human lung fibroblasts in vitro (abstract). Am. J. Respir. Crit. Care Med. 153:A403. 16. Raghu, G. 1995. Interstitial lung disease: a diagnostic approach. Am. J. Respir. Crit. Care Med. 151:909 914. 17. American Thoracic Society. 1991. Lung function testing: selection of reference values and interpretative strategies. Am. Rev. Respir. Dis. 144:1202 1218. 18. Breslow, N. E., and N. E. Day. 1987. Statistical Methods in Cancer Research, Vol. II: The Design and Analysis of Cohort Studies. International Agency for Research on Cancer, Lyon, France. 19. Raghu, G., W. J. Depaso, K. Cain, S. P. Hammar, C. E. Wetzel, D. F. Dreis, et al. 1991. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. 144:291 296. 20. Johnson, M. A., S. Swan, N. J. C. Snell, A. J. Nunn, J. H. Darbyshire, and M. Turner-Warwick. 1989. Randomized, controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 44: 280 288. 21. Erbes, R., and G. Schabert. 1997. Lung function tests in patients with IPF: are they helpful for predicting outcome? Chest 111:51 57. 22. Hanson, D., R. H. Winterbauer, S. H. Kirtland, and R. Wu. 1995. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 108:305 310. 23. Carrington, C. B., E. A. Gaensler, R. E. Coutu, et al. 1978. Natural history and treated course of usual and desquamative interstitial pneumonia. N. Engl. J. Med. 298:801 809. 24. Gulsvik, A., A. Kjelsberg, A. Bergmann, and S. S. Froland. 1986. High dose intravenous methylprednisolone pulse therapy as initial treatment in cryptogenic fibrosing alveolitis: a pilot study. Respiration 50: 252. 25. Meier-Sydow, J., M. Rust, and H. Kroneneberger. 1979. Long-term follow-up of lung function parameters in patients with idiopathic pulmonary fibrosis treated with prednisone and azathioprine or D-penicillamine. Prax Pneumol. 33:680 688. 26. Cherniack, R. M., R. G. Crystal, and A. R. Kalica. 1991. Current concepts in idiopathic pulmonary fibrosis: a road map for the future. NHLBI Workshop Summary. Am. Rev. Respir. Dis. 143:680 683. 27. Raghu, G., and M. Kinsella. 1992. Cytokine effects on extracellular matrix. In J. Kelly, editor. Cytokines in the Lung, Vol. 61. In C. Lenfant, executive editor. Lung Biology in Health and Disease. Marcel Dekker, New York. 491 543. 28. Raghu, G., Y. Chen, V. Rusch, and P. S. Rabinovitch. 1988. Differential proliferation of cultured cells from normal and fibrotic human lungs. Am. Rev. Respir. Dis. 138:703 708. 29. Rochester, C. L., and J. A. Elias. 1993. Cytokines and cytokine networking in the pathogenesis of interstitial and fibrotic lung disorders. 14: 389 416. 30. Raghu, G., S. Masta, D. Meyers, and A. S. Narayanan. 1989. Collagen synthesis by normal and fibrotic human lung fibroblasts and the effect of transforming growth factor-. Am. Rev. Respir. Dis. 140:95 100. 31. Douglas, W. W., J. H. Ryu, J. Swensen, P. Offord, D. R. Schroeder, et al. 1998. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 158:220 225. 32. Narayanan, A. S., J. Whithey, A. Souza, and G. Raghu. 1992. Effect of -interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest 101:1326 1331. 33. Katzenstein, A. A., and R. F. Fiorelli. 1994. Nonspecific interstitial pneumonia/fibrosis: histologic features and clinical significance. Am. J. Surg. Pathol. 18:136 147.